血浆代谢组学识别关键代谢物并改善糖尿病视网膜病变预测:跨国队列的开发与验证
代谢指纹在完全留出的测试集中显著改善糖尿病视网膜病变发生的预测能力,简约指纹在外部队列中同样改善发生和进展的预测,乳酸和柠檬酸与黄斑及视盘区域微血管损伤相关。
要点
- 在168种代谢物中,118种被识别为未来糖尿病视网膜病变发生的候选代谢指纹。
- 代谢指纹在完全留出的测试集中将糖尿病视网膜病变发生的C统计量从0.751提升至0.802。
- 简约指纹在外部广州队列中改善发生预测(C统计量0.807 vs 0.617)和进展预测(C统计量0.797 vs 0.665)。
核心结论
- 代谢组学分析可能有效识别稳健的代谢指纹,用于预测未来糖尿病视网膜病变的发生和进展。
- 该研究为糖尿病视网膜病变早期和晚期病理生理学提供了新见解。
研究设计与样本
- 英国生物银行队列中糖尿病视网膜病变由ICD-10编码确定,广州队列采用修订的ETDRS分级标准。
- 通过核磁共振检测识别纵向糖尿病视网膜病变代谢指纹,在完全留出的测试集中评估预测价值,并在广州队列中进行外部验证和推断分析。
主要发现
- 在168种代谢物中,118种被识别为未来糖尿病视网膜病变发生的候选代谢指纹。
- 代谢指纹在完全留出的测试集中显著改善糖尿病视网膜病变发生的预测能力,C统计量0.802(95%CI 0.760-0.843) vs 0.751(95%CI 0.706-0.796),P=5.56×10^-4。
- 在广州外部验证队列中,简约可重复指纹对糖尿病视网膜病变发生的预测C统计量为0.807(95%CI 0.711-0.903) vs 0.617(95%CI 0.494-0.740),P=1.68×10^-4;对进展的预测C统计量为0.797(95%CI 0.712-0.882) vs 0.665(95%CI 0.545-0.784),P=0.003。
- 两个队列中净分类改善(NRI)、综合判别改善(IDI)和临床有用性均有改善(所有P<0.05)。
- 在中国广州糖尿病眼病研究队列中,乳酸和柠檬酸与黄斑及视盘区域微血管损伤相关(所有P<0.05)。
关键数值与推荐
- 英国生物银行队列中,代谢指纹预测糖尿病视网膜病变发生的C统计量为0.802(95%CI 0.760-0.843) vs 传统指标0.751(95%CI 0.706-0.796),P=5.56×10^-4。
- 广州糖尿病眼病研究队列中,简约指纹预测糖尿病视网膜病变发生的C统计量为0.807(95%CI 0.711-0.903) vs 0.617(95%CI 0.494-0.740),P=1.68×10^-4。
- 广州糖尿病眼病研究队列中,简约指纹预测糖尿病视网膜病变进展的C统计量为0.797(95%CI 0.712-0.882) vs 0.665(95%CI 0.545-0.784),P=0.003。
- 两个队列中NRI、IDI和临床有用性改善的所有P<0.05。
- 广州队列中乳酸和柠檬酸与黄斑及视盘区域微血管损伤相关的所有P<0.05。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify longitudinal metabolomic fingerprints of diabetic retinopathy (DR) and to evaluate their usefulness in predicting DR development and progression. DESIGN: Multicenter, multiethnic cohort study. PARTICIPANTS: This study included 17 675 participants from the UK Biobank (UKB) who had baseline prediabetes or diabetes, identified in accordance with the 2021 American Diabetes Association guidelines, and were free of baseline DR and an additional 638 participants with type 2 diabetes mellitus from the Guangzhou Diabetic Eye Study (GDES) for external validation. Diabetic retinopathy was determined by ICD-10 codes in the UKB cohort and revised ETDRS grading criteria in the GDES cohort. METHODS: Longitudinal DR metabolomic fingerprints were identified through nuclear magnetic resonance (NMR) assay in UKB participants. The predictive value of these fingerprints for predicting DR development were assessed in a fully withheld test set. External validation and extrapolation analyses of DR progression and microvascular damage were conducted in the GDES cohort using NMR technology. Model assessments included the concordance (C) statistic, net classification improvement (NRI), integrated discrimination improvement (IDI), calibration, and clinical usefulness in both cohorts. MAIN OUTCOME MEASURES: DR development and progression and retinal microvascular damage. RESULTS: Of 168 metabolites, 118 were identified as candidate metabolomic fingerprints for future DR development. These fingerprints significantly improved the predictability for DR development beyond traditional indicators (C statistic, 0.802 [95% confidence interval (CI), 0.760-0.843] vs. 0.751 [95% CI, 0.706-0.796]; P = 5.56 × 10-4). Glucose, lactate, and citrate were among the fingerprints validated in the GDES cohort. Using these parsimonious and replicable fingerprints yielded similar improvements for predicting DR development (C statistic, 0.807 [95% CI, 0.711-0.903] vs. 0.617 [95% CI, 0.494-0.740]; P = 1.68 × 10-4) and progression (C statistic, 0.797 [95% CI, 0.712-0.882] vs. 0.665 [95% CI, 0.545-0.784]; P = 0.003) in the external GDES cohort. Improvements in NRIs, IDIs, and clinical usefulness also were evident in both cohorts (all P < 0.05). In addition, lactate and citrate were associated with microvascular damage across macular and optic nerve head regions among Chinese GDES (all P < 0.05). CONCLUSIONS: Metabolomic profiling may be effective in identifying robust fingerprints for predicting future DR development and progression, providing novel insights into the early and advanced stages of DR pathophysiology. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Yang S, Liu R, Xin Z, et al. Plasma Metabolomics Identifies Key Metabolites and Improves Prediction of Diabetic Retinopathy: Development and Validation across Multinational Cohorts. Ophthalmology. 2024. PMID: 38972358. doi:10.1016/j.ophtha.2024.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。